FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310536473> ?p ?o ?g. }

• W4310536473 endingPage "6396" @default.
• W4310536473 startingPage "6380" @default.
• W4310536473 abstract "The revolution in treatment of patients with chronic hepatitis C virus (HCV) infection dates back to the introduction of direct-acting antivirals (DAAs). The increase in efficacy was most pronounced in patients infected with genotype (GT) 1b, as this was the most poorly responsive population to treatment during the interferon era.To identify the most effective interferon-free therapy for GT1b-infected patients and to determine positive and negative predictors of virological response.This real-world retrospective analysis included patients chronically infected with GT1b HCV whose data were obtained from the multicenter observational EpiTer-2 database. Treatment effectiveness was evaluated for each therapeutic regimen as the percentage of sustained virological responses (SVR). Assessment of the safety was based on the evaluation of the course of therapy, the occurrence of adverse events including serious ones, deaths during treatment and in the post 12-wk follow-up period.The studied population consisted of 11385 patients with a mean age of 53 ± 14.8 years and a female predominance (53.4%). The majority of them were treatment-naïve (74.6%) and patients with cirrhosis accounted for 24.3%. Of the DAA regimens used, 76.9% were GT-specific with ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin being the most used option (32.4%). A total of 10903 patients responded to treatment resulting in a 98.1% in the per-protocol analysis after excluding 273 patients without SVR data. The effectiveness of all regimens exceeded 90% and the highest SVR of 98.9% was achieved in patients treated with a combination of glecaprevir/pibrentasvir. Logistic regression analyses showed that the virologic response was independently associated with female sex [odds ratio (OR) = 1.67], absence of decompensated cirrhosis at baseline (OR = 2.42) and higher baseline platelets (OR = 1.004 per 1000/μL increase), while the presence of human immunodeficiency virus (HIV) coinfection significantly decreased the odds of response (OR = 0.39). About 95%-100% of patients completed therapy irrespective of the drug regimen. At least one adverse effect occurred in 10.9%-36.3% and most of them were mild. No treatment related deaths have been reported.We documented very high effectiveness and a good safety profile across all DAA regimens. Positive predictors of SVR were female sex, absence of decompensated cirrhosis at baseline and higher platelet count while HIV coinfection reduced the effectiveness." @default.
• W4310536473 created "2022-12-11" @default.
• W4310536473 creator A5011110351 @default.
• W4310536473 creator A5039184172 @default.
• W4310536473 creator A5040261650 @default.
• W4310536473 creator A5042837669 @default.
• W4310536473 creator A5054816446 @default.
• W4310536473 creator A5056525612 @default.
• W4310536473 creator A5058746547 @default.
• W4310536473 creator A5059817040 @default.
• W4310536473 creator A5067494229 @default.
• W4310536473 creator A5068458474 @default.
• W4310536473 creator A5072500516 @default.
• W4310536473 creator A5072771020 @default.
• W4310536473 creator A5083182392 @default.
• W4310536473 creator A5088500414 @default.
• W4310536473 creator A5090001950 @default.
• W4310536473 creator A5090026807 @default.
• W4310536473 creator A5091573769 @default.
• W4310536473 date "2022-12-07" @default.
• W4310536473 modified "2023-10-05" @default.
• W4310536473 title "Best therapy for the easiest to treat hepatitis C virus genotype 1b-infected patients" @default.
• W4310536473 cites W1732930179 @default.
• W4310536473 cites W1881390415 @default.
• W4310536473 cites W2017695035 @default.
• W4310536473 cites W2030175586 @default.
• W4310536473 cites W2042063943 @default.
• W4310536473 cites W2112876622 @default.
• W4310536473 cites W2114985397 @default.
• W4310536473 cites W2266909385 @default.
• W4310536473 cites W2320330796 @default.
• W4310536473 cites W2411176684 @default.
• W4310536473 cites W2416221744 @default.
• W4310536473 cites W2485759496 @default.
• W4310536473 cites W2504681679 @default.
• W4310536473 cites W2510623134 @default.
• W4310536473 cites W2517875316 @default.
• W4310536473 cites W2519327766 @default.
• W4310536473 cites W2531545597 @default.
• W4310536473 cites W2586826494 @default.
• W4310536473 cites W2587883801 @default.
• W4310536473 cites W2588807981 @default.
• W4310536473 cites W2607344815 @default.
• W4310536473 cites W2616939364 @default.
• W4310536473 cites W2617500612 @default.
• W4310536473 cites W2620079105 @default.
• W4310536473 cites W2746084941 @default.
• W4310536473 cites W2750407738 @default.
• W4310536473 cites W2766856516 @default.
• W4310536473 cites W2777014851 @default.
• W4310536473 cites W2784719900 @default.
• W4310536473 cites W2802849236 @default.
• W4310536473 cites W2947549657 @default.
• W4310536473 cites W2951737729 @default.
• W4310536473 cites W2953687487 @default.
• W4310536473 cites W2966216116 @default.
• W4310536473 cites W2982819257 @default.
• W4310536473 cites W2995340471 @default.
• W4310536473 cites W3004888045 @default.
• W4310536473 cites W3016765842 @default.
• W4310536473 cites W3047521620 @default.
• W4310536473 cites W3088020815 @default.
• W4310536473 cites W3092351665 @default.
• W4310536473 cites W3135018183 @default.
• W4310536473 cites W3176538919 @default.
• W4310536473 cites W3202115316 @default.
• W4310536473 cites W3206517792 @default.
• W4310536473 cites W4285611660 @default.
• W4310536473 doi "https://doi.org/10.3748/wjg.v28.i45.6380" @default.
• W4310536473 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36533109" @default.
• W4310536473 hasPublicationYear "2022" @default.
• W4310536473 type Work @default.
• W4310536473 citedByCount "0" @default.
• W4310536473 crossrefType "journal-article" @default.
• W4310536473 hasAuthorship W4310536473A5011110351 @default.
• W4310536473 hasAuthorship W4310536473A5039184172 @default.
• W4310536473 hasAuthorship W4310536473A5040261650 @default.
• W4310536473 hasAuthorship W4310536473A5042837669 @default.
• W4310536473 hasAuthorship W4310536473A5054816446 @default.
• W4310536473 hasAuthorship W4310536473A5056525612 @default.
• W4310536473 hasAuthorship W4310536473A5058746547 @default.
• W4310536473 hasAuthorship W4310536473A5059817040 @default.
• W4310536473 hasAuthorship W4310536473A5067494229 @default.
• W4310536473 hasAuthorship W4310536473A5068458474 @default.
• W4310536473 hasAuthorship W4310536473A5072500516 @default.
• W4310536473 hasAuthorship W4310536473A5072771020 @default.
• W4310536473 hasAuthorship W4310536473A5083182392 @default.
• W4310536473 hasAuthorship W4310536473A5088500414 @default.
• W4310536473 hasAuthorship W4310536473A5090001950 @default.
• W4310536473 hasAuthorship W4310536473A5090026807 @default.
• W4310536473 hasAuthorship W4310536473A5091573769 @default.
• W4310536473 hasBestOaLocation W43105364731 @default.
• W4310536473 hasConcept C126322002 @default.
• W4310536473 hasConcept C142462285 @default.
• W4310536473 hasConcept C197934379 @default.
• W4310536473 hasConcept C203014093 @default.
• W4310536473 hasConcept C2522874641 @default.
• W4310536473 hasConcept C2776408679 @default.

• next